Ceram signs agreement with AstraZeneca

Published: 18-Jan-2013
Research & Development

Will develop controlled release technology for delivery of selected AZ compounds


Anglo-Swedish pharmaceutical manufacturer AstraZeneca has signed an agreement with Ceram Research in which Ceram will develop its inorganic-based controlled release technology in a feasibility study for the delivery of selected AstraZeneca compounds.

‘This technology, if successfully implemented, could provide AstraZeneca with an alternative formulation approach for delivering these compounds,’ said Tony Kinsella, CEO of Ceram, a materials development company headquartered in Stoke-on-Trent, Staffordshire, UK.

Controlled release technology is just one of the development projects that Ceram’s team of materials experts is currently working on; others include multi-element substituted hydroxyapatite for orthopaedic device coating applications.

  • Companies:
  • AstraZeneca
  • Lucideon
See more

You may also like

Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

Read more
The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license The licensing deal with Chiome enhances its open innovation platform
  3. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  4. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  5. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Drug Delivery

AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial

The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously
Research & Development

AstraZeneca's asthma-targeting Airsupra meets primary endpoint in Phase III trial

The inhaled therapeutic has proven effective in reducing the risk of severe asthma attacks in patients with intermittent or persistent asthma
Drug Delivery

Aptamer and AstraZeneca to determine the efficacy of targeted siRNA delivery vehicle

AstraZeneca is providing Aptamer with siRNAs to test if its Optima fibrotic liver technology can successfully facilitate the delivery and cell integration of therapeutic RNA
Research & Development

BenevolentAI and AstraZeneca collaboration leads to novel lupus target discovery

The novel target will be added to AstraZeneca's drug development pipeline for lupus, an autoimmune disease with significant unmet needs in the patient population
Research & Development

AstraZeneca presents data at ATS 2024 highlighting tezepelumab’s potential in treating COPD

Late-breaking results from the Phase IIa COURSE trial provide insight into tezepelumab's impact on COPD exacerbations in patients with a broad range of eosinophil levels
Research & Development

BenevolentAI and AstraZeneca collaboration finds novel heart failure target

The heart failure target was discovered through an AI platform, with AstraZeneca then experimentally validating its clinical potential
Research & Development

COVID-19 still a significant risk for the immunocompromised, study finds

AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Subscribe now